OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer

Feng Wen; Hanrui Zheng; Pengfei Zhang; David Hutton; Qiu Li

doi:10.1136/bmjopen-2017-020128

OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer

BMJ Open ◽

10.1136/bmjopen-2017-020128 ◽

2018 ◽

Vol 8 (4) ◽

pp. e020128 ◽

Cited By ~ 7

Author(s):

Feng Wen ◽

Hanrui Zheng ◽

Pengfei Zhang ◽

David Hutton ◽

Qiu Li

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Asian Patients ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Optimal and Ensure Trials - Based Combined Cost-Effectiveness Analysis of Erlotinib Versus Chemotherapy for the First- Line Treatment of Asian Patients with Nonsquamous Non– Small-Cell Lung Cancer

Value in Health ◽

10.1016/j.jval.2016.08.274 ◽

2016 ◽

Vol 19 (7) ◽

pp. A888-A889

Author(s):

F Wen ◽

H Zheng ◽

P Zhang ◽

DW Hutton ◽

Q Li

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Asian Patients ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

In response to She et al., “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater”

Lung Cancer ◽

10.1016/j.lungcan.2020.06.014 ◽

2020 ◽

Vol 146 ◽

pp. 385-386

Author(s):

Min Huang ◽

Ralph P. Insinga ◽

Thomas Burke ◽

Ying Zhang ◽

Gilberto de Lima Lopes

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN36 Cost-Effectiveness Analysis of Pembrolizumab Versus Nivolumab As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer in Germany

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.086 ◽

2020 ◽

Vol 22 ◽

pp. S11

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Management and Research ◽

10.2147/cmar.s293983 ◽

2021 ◽

Vol Volume 13 ◽

pp. 4263-4270

Author(s):

Longfeng Zhang ◽

Na Li ◽

Maobai Liu ◽

Bin Zheng ◽

Zhijuan Wu ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN37 Cost-Effectiveness Analysis of Pembrolizumab Versus Nivolumab As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer in France

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.087 ◽

2020 ◽

Vol 22 ◽

pp. S11

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non–small-cell lung cancer in China

European Journal of Hospital Pharmacy ◽

10.1136/ejhpharm-2020-002208 ◽

2020 ◽

pp. ejhpharm-2020-002208

Author(s):

Yuan Jiang ◽

Xingwei Wang

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Standard Chemotherapy ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN175 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB VERSUS CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC NON-SMALL CELL LUNG CANCER WITH DIFFERENT PD-L1 EXPRESSION LEVELS IN CHINA USING BOTH PARTITION SURVIVAL AND MARKOV MODELS

Value in Health ◽

10.1016/j.jval.2020.04.1656 ◽

2020 ◽

Vol 23 ◽

pp. S53-S54

Author(s):

H. Xu ◽

A.X. Ma

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Markov Models ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN105 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB VERSUS NIVOLUMAB AS THE FIRST-LINE TREATMENT FOR ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER IN UNITED KINGDOM

Value in Health ◽

10.1016/j.jval.2020.04.1599 ◽

2020 ◽

Vol 23 ◽

pp. S41

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

United Kingdom ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater

Lung Cancer ◽

10.1016/j.lungcan.2019.10.017 ◽

2019 ◽

Vol 138 ◽

pp. 88-94 ◽

Cited By ~ 10

Author(s):

Longjiang She ◽

Huabin Hu ◽

Mengting Liao ◽

Xuefeng Xia ◽

Yin Shi ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives

Annals of Translational Medicine ◽

10.21037/atm-21-4294 ◽

2021 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

Shuqiao Cheng ◽

Rui Pei ◽

Jianhuang Li ◽

Bin Li ◽

Lanhua Tang ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text